Skip to main content
. 2022 Feb 1;10(2):e004025. doi: 10.1136/jitc-2021-004025

Figure 1.

Figure 1

Tumor response. The best tumor percentage change from baseline in response to atezolizumab with bevacizumab by PD-L1 TPS (50%–74% and 75%–100%). Tumor responses were measured as the sum of the longest diameters of target lesions by an independent review committee. PD-L1 TPS, programmed death ligand 1 tumor proportion score.